BofA update shows where active managers are putting money
BEIJING - Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare Group Co., Ltd. (HKSE:2453), has completed China’s first proton therapy treatment for a patient with choroidal malignant melanoma, according to a press release issued Monday. The company, with a market capitalization of $22.8 million and annual revenue of $52.6 million, has been expanding its specialized cancer treatment facilities despite challenging market conditions.
The procedure, performed on July 11, utilized pencil beam scanning proton therapy with real-time image guidance to target the eye tumor while preserving surrounding tissues. This approach offers an alternative to enucleation, the traditional treatment that involves complete eye removal.
Choroidal malignant melanoma is a common intraocular cancer that typically requires eye removal, resulting in permanent blindness and facial appearance changes for patients.
The Guangzhou facility, which is the first medical institution in China to offer proton therapy for this specific condition, aims to provide a treatment option that preserves the eye while effectively treating the cancer.
Concord Healthcare Group is a subsidiary of Concord Medical Services Holdings Limited (NYSE:CCM), which provides oncology healthcare services through a network of self-owned and partnered hospitals across China. Concord Healthcare’s H shares were listed on the Hong Kong Stock Exchange in January 2024.
The company offers cancer diagnosis, treatment, education and prevention services, and equips its facilities with advanced technology including proton therapy systems.
The information was disclosed in a company press release.
In other recent news, Concord Medical Services Holdings Ltd has announced several significant developments involving its subsidiary, Concord Healthcare Group Co., Ltd. The company disclosed that Concord Healthcare has completed a share placement on the Main Board of The Stock Exchange of Hong Kong Limited, successfully allocating 18.6 million placing shares at a price of HK$5.38 each. Additionally, Concord Medical reported a change in the controlling shareholders of Concord Healthcare, although specific details about the parties involved were not provided. In another development, Concord Medical’s major shareholder, Shanghai Medstar, has increased its stake in Concord Healthcare by purchasing 95,400 H shares on the open market. This transaction follows a similar acquisition of 45,600 H shares by Shanghai Medstar earlier in May 2025. These moves are seen as a sign of confidence in Concord Medical’s ongoing development. Furthermore, Concord Healthcare issued a supplemental announcement regarding its 2024 annual report, providing additional information about its proton therapy services. These updates reflect Concord Medical’s active engagement in enhancing its market presence and shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.